The original claim, posted by STAT News on X, stated that a personalized mRNA cancer vaccine "succeeded in a late-stage melanoma study" and that the results "could herald a new, powerful approach in oncology." When this claim was first checked, the available evidence came from the Phase 2b KEYNOTE-942 study, a mid-stage trial of 157 patients whose five-year follow-up data showed a 49% reduction in recurrence or death. At that time, the Phase 3 INTerpath-001 trial was still ongoing, and the claim's "late-stage" characterization was inaccurate.
That situation has now changed decisively. On August 19, 2026, Merck and Moderna announced positive interim results from the Phase 3 INTerpath-001 trial. STAT News, the original source of the claim, reported that the vaccine "succeeded in a late-stage melanoma trial," describing it as "the first randomized Phase 3 clinical trial aimed at definitively proving" the benefit of neoantigen vaccines. Reuters, republished by USA Today, confirmed this was "the first positive late-stage trial results for an mRNA cancer vaccine," and CNN corroborated the same finding.
The new evidence is specific and consistent across multiple independent outlets. The Phase 3 trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma whose tumors had been surgically removed. Patients were randomized to receive Merck's Keytruda plus Moderna's personalized mRNA vaccine (intismeran) or Keytruda alone for about one year. The interim results showed the combination met both its primary endpoint of reducing cancer recurrence and its secondary endpoint of preventing distant metastasis. No new safety signals emerged, and the companies said they would present full data at an upcoming medical meeting and share it with regulators.
The market reaction underscored the significance of the result: Moderna's shares surged roughly 60–90% in premarket trading, and Merck climbed about 7.5%. Analysts from William Blair said the interim results position both companies to seek regulatory approval, while J.P. Morgan analysts called the launch key to Moderna's return to profitability. Barclays projected the therapy could generate about $3 billion in melanoma revenue by 2035.
The earlier Phase 2b data remains relevant context but is no longer the sole or primary evidence. The January 2026 five-year follow-up from the mid-stage KEYNOTE-942 study, which showed a 49% reduction in recurrence or death, helped build confidence in the Phase 3 readout. The BioSpace ASCO coverage and the Merck press release from that earlier period are still useful for understanding the vaccine's mechanism and prior efficacy signals, but they have been superseded by the Phase 3 interim results for the purpose of evaluating the claim.
The verdict has changed from "misleading" to "supported" because the central factual assertion of the claim, that the vaccine succeeded in a late-stage melanoma study, is now directly confirmed by the Phase 3 INTerpath-001 interim readout reported by STAT News, Reuters, and CNN on August 19, 2026. The characterization of the results as potentially heralding a new approach in oncology is consistent with analyst commentary and the trial's status as the first positive Phase 3 result for an mRNA cancer vaccine.
